Soluble glucan protects against endotoxin shock in the rat: The role of the scavenger receptor

Shock

Volumn 9, Issue 3, 1998, Pages 193-198

  Vereschagin, Eugene I ^a   Van Lambalgen, Antonie A ^b   Dushkin, Mikhail I ^a   Schwartz, Yakov Sh ^a   Polyakov, Lev ^a   Heemskerk, Astrid ^b   Huisman, Evelien ^b   Thijs, Lambert G ^b   Van Den Bos, Gerard C ^b  

^a NOVOSIBIRSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; ACETYL-LDL; BETA GLUCAN; CARBOXYMETHYL BETA 1,3 GLUCAN; CARBOXYMETHYL-BETA-1,3-GLUCAN; GLUCAN; IMMUNOGLOBULIN RECEPTOR; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; RADIOACTIVE IODINE; SCARB1 PROTEIN, MOUSE; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; CHEMOLUMINESCENCE; DRUG EFFECT; HEMODYNAMICS; KIDNEY; LEUKOCYTE; LIVER; MACROPHAGE; MALE; METABOLISM; MORTALITY; PHYSIOLOGY; RAT; SEPTIC SHOCK; SURVIVAL RATE; WISTAR RAT;

ANIMALS; BETA-GLUCANS; CHEMILUMINESCENT MEASUREMENTS; GLUCANS; HEMODYNAMIC PROCESSES; IODINE RADIOISOTOPES; KIDNEY; LEUKOCYTES; LIPOPROTEINS, LDL; LIVER; MACROPHAGES; MALE; MEMBRANE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOPROTEIN; RECEPTORS, SCAVENGER; SCAVENGER RECEPTORS, CLASS B; SHOCK, SEPTIC; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032011467     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199803000-00006     Document Type: Article

References (36)

1. Di Luzio NR: Immunopharmacology of glucan: Broad spectrum enhancer of host defense mechanisms. Trends Pharmacol Sci 4:344-347, 1983.
2. Chihara G, Maeda YY, Suga T, Hamuro J: Lentinan as a host defence potentiator. Int J Immunother 4:145-154, 1989.
3. Vereschagin EI, Korolenko TA, Arkhipov SA: The role of A1-proteinase inhibitor in semisoluble Glucan-induced resistance to hemorrhage. In Fritz H. (ed): Agents & Actions Supplements 38/III, Recent Progress on Kinins, Basel, Switzerland: Birkhauser-Verlag, 1992, pp 385-388.
4. Tzianabos AO, Cisneros RL: Prophylaxis with the immunomodulator PGG glucan enhances antibiotic-resistant efficacy in rats infected with antibiotic-resistant bacteria. Ann NY Acad Sci 797:285-287, 1996.
5. Williams DL, Sherwood ER, Brouder IW, McNamee RB, Jones EL, Di Luzio NR: The role of complement Glucan-induced protection against septic shock. Circ Shock 25:53-60, 1988.
6. Moore JN, Cook JAC, Morris DD, Halushka PV, Wise WC: Endotoxin-induced procoagulant activity, eicosanoid synthesis, and tumor necrosis factor production by rat peritoneal macrophages: Effect of endotoxin tolerance and glucan. Circ Shock 31:281-295, 1990.
7. Kery V, Novotny L, Tihlarik K, et al: Preparation, properties and anti-leukemic activity of arabinosylcytosine polysaccharide conjugates. Int J Biochem 22:1203-1207, 1990.
8. Pospesil M, Vacek A, Hofer M, Viklicka S, Pipalova I, Sandula J: Hyporesponsiveness of murine myeloid progenitor cells to glucan following its repeated administration. Folia Biologica 39:178-187, 1993.
9. Babineau TJ, Marcello P, Swails W, Kenler A, Bristian B, Forse RA: Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 220:601-609, 1994.
10. Goris RJ: Multiple organ failure: Whole body inflammation? Schwei Med-Wochenschr 119:347-353, 1989.
11. Redl H, Schlag G: Pathophysiology of multiple organ failure (MOF): Proposed mechanisms. Clin Intens Care 1:66-71, 1990.
12. Griesman SE, Young EJ, Carozza FA: Mechanism of endotoxin tolerance: Specificity of the early and late phases of pyrogenic tolerance. J Immunol 103:1223-1236, 1969.
13. Sheppard BC, Fraker DI, Norton J: Prevention, treatment of endotoxin and sepsis lethality with recombinant tumor necrosis factor. Surgery 106:156-161, 1989.
14. Astiz ME, Saha DC, Brooks K, Caprati CM, Rackow EC: Comparison of the induction of endotoxin tolerance in endotoxemia and peritonitis by monophosphoryl lipid A and lipopolysaccharide. Circ Shock 39:194-198, 1993.
15. Grunwald U, Kruger Ch, Schutt Ch: Endotoxin-neutralizing capacity of soluble CD14 is a highly conserved specific function. Circ Shock 39:220-225, 1993.
16. Hampton RY, Krieger M: Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 352:342-344, 1991.
17. Schmid Schönbein GW: The damaging potential of leukocyte activation in the microcirculation. Angiology 44:45-56, 1994.
18. Strohmaier W, Redl H, Schlag G, Inthorn D: D-Erythro-neopterin plasma levels in intensive care patients with, without septic complications. Crit Care Med 15:757-763, 1987.
19. Hoekstra OS, van Lambalgen AA, Groeneveld ABJ, van den Bos GC, Thijs LG: Thermodilution compared with microspheres under different flow conditions. Intensive Care Med 16(Suppl 1):S1, 1990.
20. Van Lambalgen AA, van Kraats AA, van den Bos GC, et al: Renal function and metabolism during endotoxemia in rats: Role of hypoperfusion. Circ Shock 35:164-173, 1991.
21. Sapirstein LA, Vidt DG, Mandel MJ, et al: Volumes of distribution and clearance of intravenously injected creatinine in the dog. Am J Physiol 181:330-336, 1951.
22. 2 and prostacyclin production by lipopolysaccharide-stimulated peritoneal macrophages. J Reticuloendothelial Soc 30:445-450, 1981.
23. Evans GF, Snydef YM, Butler LD, Zuckerman SH: Differential expression of IL-1 and tumor necrosis factor in murine septic shock models. Circ Shock 29:279-290, 1989.
24. Brown MS, Ho YK, Goldstein JL: The cholesteryl ester cycle in macrophage foaming cells. J Biol Chem 255:9344-9352, 1980.
25. Bilheimer DW, Tisenberg S, Levy RJ: The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochem Biophys Acta 260:212-221, 1972.
26. Goldstein JL, Brown MS: Binding and degradation of low density lipoproteins by cultured human fibroblasts. J Biol Chem 249:5153-5162, 1974.
27. Van Lambalgen AA, Bronsveld W, van den Bos GC, Thijs LG: Distribution of cardiac output, oxygen consumption and lactate production in canine endotoxin shock. Cardiovasc Res 18:195-205, 1984.
28. Mulder MF: Systemic and regional hemodynamic changes during endotoxemia in rats: Role of mediators and low cardiac output. Amsterdam: Vrije Universiteit; 1994. PhD Thesis.
29. Heemskerk AEJ, Huisman E, van Lambalgen AA, van den Bos GC, Thijs LG, Tangelder GJ: Laparotomy and renal function during endotoxin shock in rats. Shock 6:410-417, 1996.
30. Madonna GS, Vogel SN: Early tolerance to endotoxin is associated with alteration in bone-marrow-derived macrophage precursor pools. J Immunol 135:3763-3769, 1985.
31. Nast-Kolb D, Waydhas C, Jochum M, Duswald KN, Spannagl M, Schramm M, Fritz H, Schweiberer L: Biochemische factoren als objective parameter zur prognoseabschatzung beim polytrauma. Unfallchirurg 95: 59-66, 1992.
32. Herodin F, Benichou G: Transient suppression of the zymosan-induced chemiluminescence produced by bone marrow cells during a subcutaneous nonspecific inflammation in the mouse. J Leukocyte Biol 42: 76-83, 1987.
33. Bittner C, Parnham MJ: Alteration by prostaglandins and indomethacin of the mouse peritoneal macrophage oxydative burst. Br J Pharmacol 79: 343P, 1983.
34. Blomhoff R, Drevon CA, Eskild W, Helgerud P, Norum KR, Berg T: Clearance of acetyl low density lipoprotein by rat liver endothelial cells. J Biol Chem 259:8898-8903, 1984.
35. Erroi A, Fantuzzi G, Mengozzi M, et al: Differential regulation of cytokine production in lipopolysaccharide tolerance in mice. Infect Immun 61: 4356-4359, 1993.
36. Hafenrichter DG, Roland CR, Mangino MJ, Flye MW: The Kupffer cell in endotoxin tolerance: Mechanisms of protection against lethal endotoxemia. Shock 2:251-256, 1993.